EDESA BIOTECH, INC. Depreciation
EDESA BIOTECH, INC. (EDSA) reported Depreciation of $8.70 thousand for the 12-month period ending 2024-09-30, per its 10-K filed 2024-12-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2024-12-13
- EDESA BIOTECH, INC. depreciation for the quarter ending 2021-09-30 was $1.91B, a 25.31% decline year-over-year.
- EDESA BIOTECH, INC. depreciation for the quarter ending 2021-06-30 was $2.48B, a 24.55% increase year-over-year.
- EDESA BIOTECH, INC. depreciation for the quarter ending 2021-03-31 was $1.62K, a 38.93% decline year-over-year.
- EDESA BIOTECH, INC. depreciation for the quarter ending 2020-12-31 was $1.62K, a 32.63% decline year-over-year.
- EDESA BIOTECH, INC. depreciation for fiscal 2024 was $8.70K, a 101.06% increase from fiscal 2023.
- EDESA BIOTECH, INC. depreciation for fiscal 2023 was $4.33K, a 100.00% decline from fiscal 2022.
- EDESA BIOTECH, INC. depreciation for fiscal 2022 was $6.99B, a 16.00% decline from fiscal 2021.
- EDESA BIOTECH, INC. depreciation for fiscal 2021 was $8.32B, a 13.32% decline from fiscal 2020.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 6 month as first filed | Depreciation 9 month | Depreciation 9 month as first filed | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | $8.70K 10-K · filed 2024-12-13 | |||||||
| 2023-09-30 | $4.33K 10-K · filed 2024-12-13 | $4.33B 10-K · filed 2023-12-15 | ||||||
| 2022-09-30 | $6.99B 10-K · filed 2023-12-15 | |||||||
| 2021-09-30 | $1.91B derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-16 | $4.39B derived: sum of 2 quarters · filed 2022-12-16 | $4.39B derived: sum of 3 quarters · filed 2022-12-16 | $8.32B 10-K · filed 2022-12-16 | ||||
| 2021-06-30 | $2.48B 10-Q · filed 2021-08-13 | $2.48B derived: sum of 2 quarters · filed 2021-08-13 | $6.41B 10-Q · filed 2021-08-13 | $5.04B derived: sum of 4 quarters · filed 2021-12-28 | ||||
| 2021-03-31 | $1.62K 10-Q · filed 2021-05-14 | $3.93K 10-Q · filed 2021-05-14 | $2.56B derived: sum of 3 quarters · filed 2021-12-28 | $4.55B derived: sum of 4 quarters · filed 2021-12-28 | ||||
| 2020-12-31 | $1.62K 10-Q · filed 2021-02-16 | $2.56B derived: sum of 2 quarters · filed 2021-12-28 | $4.55B derived: sum of 3 quarters · filed 2021-12-28 | $4.55B derived: sum of 4 quarters · filed 2021-12-28 | ||||
| 2020-09-30 | $2.56B derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-28 | $4.55B derived: sum of 2 quarters · filed 2021-12-28 | $4.55B derived: sum of 3 quarters · filed 2021-12-28 | $9.60B 10-K · filed 2021-12-28 | $9.60K 10-K · filed 2020-12-07 | |||
| 2020-06-30 | $1.99B 10-Q · filed 2021-08-13 | $1.99K 10-Q · filed 2020-08-12 | $1.99B derived: sum of 2 quarters · filed 2021-08-13 | $7.05B 10-Q · filed 2021-08-13 | $7.05K 10-Q · filed 2020-08-12 | $1.99B derived: sum of 4 quarters · filed 2021-08-13 | ||
| 2020-03-31 | $2.65K 10-Q · filed 2021-05-14 | $5.05K 10-Q · filed 2021-05-14 | $7.33K derived: sum of 3 quarters · filed 2021-05-14 | $9.43K derived: sum of 4 quarters · filed 2021-05-14 | ||||
| 2019-12-31 | $2.40K 10-Q · filed 2021-02-16 | $4.68K derived: sum of 2 quarters · filed 2021-02-16 | $6.78K derived: sum of 3 quarters · filed 2021-02-16 | $7.29K derived: sum of 4 quarters · filed 2021-02-16 | ||||
| 2019-09-30 | $2.28K derived: 10-K 9 month − 10-Q 6 month · filed 2020-12-07 | $4.38K derived: sum of 2 quarters · filed 2020-12-07 | $4.78K 10-K · filed 2020-12-07 | $4.80K 10-KT · filed 2019-12-12 | $5.29K derived: sum of 4 quarters · filed 2020-12-07 | |||
| 2019-06-30 | $2.10K 10-Q · filed 2020-08-12 | $1.60K 10-Q · filed 2019-08-14 | $2.50K 10-Q · filed 2019-08-14 | $3.02K 10-Q · filed 2020-08-12 | ||||
| 2019-03-31 | $504.00 10-Q · filed 2020-05-15 | $916.00 10-Q · filed 2020-05-15 | $80.16K 10-Q · filed 2019-05-08 | |||||
| 2018-12-31 | $412.00 10-Q · filed 2020-02-13 | $44.47K 10-Q · filed 2019-02-05 | $1.70K 10-KT · filed 2019-12-12 | |||||
| 2018-09-30 | $188.37K 10-K · filed 2018-11-30 | |||||||
| 2018-06-30 | $400.00 10-Q · filed 2019-08-14 | $1.00K 10-Q · filed 2019-08-14 | $96.29K derived: sum of 3 quarters · filed 2019-08-14 | |||||
| 2018-03-31 | $46.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-08 | $95.89K 10-Q · filed 2019-05-08 | ||||||
| 2017-12-31 | $49.31K 10-Q · filed 2019-02-05 | |||||||
| 2017-09-30 | $179.32K 10-K · filed 2018-11-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |